NASDAQ:AFIB

Acutus Medical Competitors

$13.20
-0.07 (-0.53 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.87
Now: $13.20
$13.46
50-Day Range
$12.97
MA: $17.15
$23.80
52-Week Range
$12.59
Now: $13.20
$38.99
Volume172,132 shs
Average Volume371,142 shs
Market Capitalization$370.85 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Acutus Medical (NASDAQ:AFIB) Vs. CSII, MDXG, ATRI, SIBN, TCMD, and LMAT

Should you be buying AFIB stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Acutus Medical, including Cardiovascular Systems (CSII), MiMedx Group (MDXG), Atrion (ATRI), SI-BONE (SIBN), Tactile Systems Technology (TCMD), and LeMaitre Vascular (LMAT).

Cardiovascular Systems (NASDAQ:CSII) and Acutus Medical (NASDAQ:AFIB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cardiovascular Systems and Acutus Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Acutus Medical04102.20

Cardiovascular Systems currently has a consensus target price of $47.5714, indicating a potential upside of 31.67%. Acutus Medical has a consensus target price of $24.80, indicating a potential upside of 87.88%. Given Acutus Medical's higher possible upside, analysts clearly believe Acutus Medical is more favorable than Cardiovascular Systems.

Profitability

This table compares Cardiovascular Systems and Acutus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Acutus Medical-1,410.17%N/A-74.36%

Earnings & Valuation

This table compares Cardiovascular Systems and Acutus Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million6.14$-27,240,000.00($0.79)-45.73
Acutus Medical$2.84 million130.58$-97,040,000.00N/AN/A

Cardiovascular Systems has higher revenue and earnings than Acutus Medical.

Institutional & Insider Ownership

89.7% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 69.6% of Acutus Medical shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cardiovascular Systems beats Acutus Medical on 8 of the 11 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and MiMedx Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acutus Medical04102.20
MiMedx Group00103.00

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. MiMedx Group has a consensus price target of $20.00, indicating a potential upside of 57.23%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than MiMedx Group.

Profitability

This table compares Acutus Medical and MiMedx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acutus Medical-1,410.17%N/A-74.36%
MiMedx Group-37.28%-404.08%-58.81%

Earnings and Valuation

This table compares Acutus Medical and MiMedx Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$2.84 million130.58$-97,040,000.00N/AN/A
MiMedx Group$299.26 million4.73$-25,580,000.00N/AN/A

MiMedx Group has higher revenue and earnings than Acutus Medical.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 4.0% of MiMedx Group shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

MiMedx Group beats Acutus Medical on 6 of the 10 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and Atrion, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acutus Medical04102.20
Atrion0000N/A

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than Atrion.

Profitability

This table compares Acutus Medical and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acutus Medical-1,410.17%N/A-74.36%
Atrion21.90%13.90%12.55%

Earnings and Valuation

This table compares Acutus Medical and Atrion's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$2.84 million130.58$-97,040,000.00N/AN/A
Atrion$155.07 million7.58$36.76 millionN/AN/A

Atrion has higher revenue and earnings than Acutus Medical.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Atrion beats Acutus Medical on 6 of the 10 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and SI-BONE, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acutus Medical04102.20
SI-BONE00503.00

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. SI-BONE has a consensus price target of $32.60, indicating a potential downside of 3.44%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than SI-BONE.

Profitability

This table compares Acutus Medical and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acutus Medical-1,410.17%N/A-74.36%
SI-BONE-61.67%-45.03%-29.29%

Earnings and Valuation

This table compares Acutus Medical and SI-BONE's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$2.84 million130.58$-97,040,000.00N/AN/A
SI-BONE$67.30 million16.42$-38,400,000.00($1.55)-21.78

SI-BONE has higher revenue and earnings than Acutus Medical.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

SI-BONE beats Acutus Medical on 7 of the 11 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Insider and Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. 5.3% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Acutus Medical and Tactile Systems Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acutus Medical-1,410.17%N/A-74.36%
Tactile Systems Technology-4.57%1.37%0.99%

Analyst Recommendations

This is a summary of recent ratings and target prices for Acutus Medical and Tactile Systems Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acutus Medical04102.20
Tactile Systems Technology01202.67

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. Tactile Systems Technology has a consensus price target of $59.00, indicating a potential upside of 9.26%. Given Acutus Medical's higher possible upside, research analysts clearly believe Acutus Medical is more favorable than Tactile Systems Technology.

Earnings and Valuation

This table compares Acutus Medical and Tactile Systems Technology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$2.84 million130.58$-97,040,000.00N/AN/A
Tactile Systems Technology$189.49 million5.59$10.97 million$0.5696.43

Tactile Systems Technology has higher revenue and earnings than Acutus Medical.

Summary

Tactile Systems Technology beats Acutus Medical on 8 of the 11 factors compared between the two stocks.

Acutus Medical (NASDAQ:AFIB) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Insider & Institutional Ownership

69.6% of Acutus Medical shares are owned by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Acutus Medical and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acutus Medical-1,410.17%N/A-74.36%
LeMaitre Vascular15.41%12.32%8.45%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Acutus Medical and LeMaitre Vascular, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acutus Medical04102.20
LeMaitre Vascular04202.33

Acutus Medical currently has a consensus price target of $24.80, indicating a potential upside of 87.88%. LeMaitre Vascular has a consensus price target of $36.60, indicating a potential downside of 28.85%. Given Acutus Medical's higher possible upside, equities analysts plainly believe Acutus Medical is more favorable than LeMaitre Vascular.

Earnings & Valuation

This table compares Acutus Medical and LeMaitre Vascular's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acutus Medical$2.84 million130.58$-97,040,000.00N/AN/A
LeMaitre Vascular$117.23 million9.01$17.93 million$0.8858.45

LeMaitre Vascular has higher revenue and earnings than Acutus Medical.

Summary

LeMaitre Vascular beats Acutus Medical on 9 of the 11 factors compared between the two stocks.


Acutus Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$36.13-0.8%$1.45 billion$236.54 million-54.74
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.72-5.0%$1.42 billion$299.26 million-13.53Gap Up
Atrion logo
ATRI
Atrion
1.1$644.00-0.3%$1.18 billion$155.07 million36.28
SI-BONE logo
SIBN
SI-BONE
1.2$33.76-0.5%$1.10 billion$67.30 million-21.10Insider Selling
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$54.00-0.9%$1.06 billion$189.49 million-120.00News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$51.44-2.0%$1.06 billion$117.23 million55.31
Cerus logo
CERS
Cerus
1.7$6.13-1.0%$1.03 billion$74.65 million-15.72Analyst Upgrade
Analyst Revision
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.55-0.0%$974.05 million$72.55 million-34.41Analyst Report
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.77-1.7%$906.52 million$264.16 million-5.32
CryoLife logo
CRY
CryoLife
2.0$22.61-0.1%$884.50 million$276.22 million-59.50
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$42.87-1.6%$836.48 million$459.95 million35.73
Surmodics logo
SRDX
Surmodics
1.3$57.14-0.9%$786.02 million$94.86 million714.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.42-0.3%$749.68 million$154.60 million-45.30
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.10-0.5%$689.46 million$123.86 million68.34Analyst Upgrade
Intersect ENT logo
XENT
Intersect ENT
1.4$20.49-1.7%$676.50 million$109.14 million-10.73News Coverage
SeaSpine logo
SPNE
SeaSpine
1.3$21.94-2.1%$612.85 million$159.08 million-13.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Vapotherm logo
VAPO
Vapotherm
1.5$23.26-0.7%$600.27 million$48.10 million-11.08News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$39.80-1.7%$570.33 million$114.51 million-84.68News Coverage
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.81-1.0%$568.96 millionN/A-9.61Analyst Downgrade
News Coverage
PAVmed logo
PAVM
PAVmed
1.2$6.00-1.8%$494.77 millionN/A-7.89
Accuray logo
ARAY
Accuray
2.3$5.21-0.6%$484.00 million$382.93 million37.21
iCAD logo
ICAD
iCAD
1.5$18.55-1.0%$462.23 million$31.34 million-19.53Analyst Upgrade
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$22.12-1.9%$457.29 million$11.22 million-50.27Gap Down
AVITA Medical logo
RCEL
AVITA Medical
1.4$21.07-0.2%$455.72 million$14.26 million-10.18Analyst Upgrade
Profound Medical logo
PROF
Profound Medical
1.6$20.50-3.9%$415.95 million$4.17 million-17.52News Coverage
Soliton logo
SOLY
Soliton
1.1$18.25-0.1%$386.90 millionN/A-24.33
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.90-0.2%$385.05 million$24.95 million-26.97
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.73-0.7%$373.97 million$198.38 million24.87
Apyx Medical logo
APYX
Apyx Medical
1.0$9.50-3.7%$326.02 million$28.15 million-20.21Analyst Downgrade
Gap Up
Neuronetics logo
STIM
Neuronetics
1.5$12.79-2.5%$324.97 million$62.66 million-7.61
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.54-1.0%$319.17 million$46.90 million27.62News Coverage
DarioHealth logo
DRIO
DarioHealth
1.1$20.62-3.9%$317.45 million$7.56 million-2.58Gap Up
IRadimed logo
IRMD
IRadimed
1.5$24.04-3.0%$295.96 million$38.52 million75.13News Coverage
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.10-2.2%$260.86 million$220,000.0011.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.53-0.7%$227.19 million$8.34 million-2.22
Titan Medical logo
TMDI
Titan Medical
1.2$1.82-7.1%$199.34 millionN/A182.00Analyst Report
Analyst Revision
News Coverage
Gap Down
TELA Bio logo
TELA
TELA Bio
2.1$13.72-0.0%$198.12 million$15.45 million-4.71
NMRD
Nemaura Medical
0.2$6.96-3.6%$159.59 millionN/A-34.80
PolyPid logo
PYPD
PolyPid
1.4$9.33-2.0%$159.04 millionN/A0.00Gap Up
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.44-0.6%$153.00 million$23.16 million-344.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.66-1.1%$147.07 million$50.71 million-4.56
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.20-1.0%$145.02 millionN/A0.00
Avinger logo
AVGR
Avinger
1.3$1.50-0.7%$142.95 million$9.13 million-1.15News Coverage
Beyond Air logo
XAIR
Beyond Air
1.7$5.95-1.8%$121.90 million$1.39 million-3.79
Venus Concept logo
VERO
Venus Concept
1.9$2.24-2.2%$120.90 million$110.41 million-0.67Gap Down
Liquidia logo
LQDA
Liquidia
1.5$2.58-1.9%$111.81 million$8.07 million-1.21Gap Up
Brainsway logo
BWAY
Brainsway
1.3$9.37-0.6%$104.24 million$23.10 million-29.28News Coverage
Pro-Dex logo
PDEX
Pro-Dex
0.7$26.89-0.4%$103.82 million$34.83 million26.97
Nephros logo
NEPH
Nephros
2.0$8.07-3.3%$79.98 million$10.33 million-17.54News Coverage
LENSAR logo
LNSR
LENSAR
1.7$7.02-1.0%$76.75 millionN/A0.00
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.